Walk into any good hospital today, and you\u2019ll notice something. Almost nothing is done the old way anymore. What used to be routine laparoscopic surgery is now done with robotic assistance because it improves precision and speeds up recovery. Cardiac bypasses, orthopaedic procedures, prostate surgeries\u2014hospitals increasingly prefer advanced, minimally invasive techniques whenever they can.<\/p>\n
And insurers, for once, aren\u2019t behind. These \u201cmodern treatments,\u201d as the industry calls them, are now part of most comprehensive health insurance plans. IRDAI has even notified 12 modern procedures that insurers cannot exclude as long as they are medically required. You\u2019ll see insurers proudly advertising \u201cModern Treatment Coverage up to Sum Insured\u201d everywhere.<\/p>\n
More customers now actively ask for this feature. Hospitals encourage it. Insurers advertise it.<\/p>\n
Sounds perfect, right?<\/p>\n
Not really. A lot can still go wrong, and that\u2019s what this article is about.<\/p>\n
Let me start with a claim we handled recently. A few months ago, we helped a customer whose mother was admitted with severe chest pain. Tests showed a 90% blockage in her LAD artery. The cardiac surgeon recommended a MICS CABG, a minimally invasive bypass technique that offers faster recovery and fewer complications than the traditional open-chest method. In insurance language, this falls under modern treatment.<\/p>\n
The hospital sent a pre-authorisation request for \u20b99 lakh, the estimated cost of treatment. The insurer approved \u20b999,000.<\/p>\n
This is not always a cause for alarm because pre-auth numbers are tentative. But in this case, the approval letter included a clear note: MICS was not part of their tariff list, so they would only pay the rate for a conventional CABG, which typically comes to around \u20b94 lakhs.<\/p>\n
This is a fairly common issue with modern treatments. Tariff agreements between insurers and hospitals are often based on older, conventional procedures. So the insurer\u2019s position was essentially: we only pay \u20b94 lakh for bypass surgeries at this hospital. If they are charging more for a newer technique, that is outside our agreement.<\/p>\n
The medical necessity of MICS did not feature in their initial assessment at all.<\/p>\n
We escalated the matter with the surgeon\u2019s justification, angiogram findings, and a request asking the insurer to point to any clause that allowed them to restrict payment. After a second review, the insurer reconsidered the tariff and eventually approved about \u20b97 lakh after hospital discounts.<\/p>\n
This case just goes on to show that modern treatment coverage on paper does not automatically translate to a full claim in practice. The feature exists, the policy mentions it, and IRDAI requires it, but the actual approval depends almost entirely on how the insurer interprets medical necessity.<\/p>\n
Even if the policy covers modern treatments, the insurer can deny or restrict the amount if the doctor hasn\u2019t clearly explained why the modern technique was essential. Without strong documentation, the claim becomes very weak during internal medical review.<\/p>\n
We recently saw this again. A patient underwent a robotic gallbladder procedure. The hospital requested cashless approval, but the insurer denied it because there was no clear explanation of why a robotic technique was required. We tried again during reimbursement with a more detailed note, but the insurer still rejected it. We\u2019re now pursuing the case with the Ombudsman.<\/p>\n
Just because a robotic or minimally invasive option is available does not automatically make it medically necessary. For instance, robotic surgeries cost substantially more because of the equipment, the setup, and the specialised teams involved. Insurers usually approve them for critical conditions like cancer, prostate disorders, and brain-related surgeries, where there is strong medical precedence that added precision genuinely improves outcomes.<\/p>\n
But for routine procedures like hernia repair or gallbladder removal, insurers often restrict or deny the robotic technique, arguing that these can be managed safely through conventional or laparoscopic methods.<\/p>\n
On the other hand, several other modern treatments, such as intravitreal injections for eye diseases or monoclonal antibody therapy for certain types of cancer, are routinely approved. These have clearer clinical indications and established medical evidence.<\/p>\n
And naturally, this creates tension. Treating doctors often push back against insurers\u2019 interpretations, especially when they believe the modern technique is in the patient\u2019s best interest. Insurers, meanwhile, rely on cost considerations and legacy tariff structures. This back-and-forth will continue until there is a stronger regulatory framework for hospitals, too, one that clearly defines when certain modern techniques are considered medically necessary and at what price.<\/p>\n
Here are a few practical steps.<\/p>\n